⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16331344 | 1.00 | — | — | |
| SCHEMBL5027985 | 1.00 | — | — | |
| SCHEMBL29283162 | 0.95 | ALDH1A1 (0.31) | — | |
| SCHEMBL29283161 | 0.95 | ALDH1A1 (0.31) | — | |
| SCHEMBL6248401 | 0.84 | — | — | |
| SCHEMBL17065711 | 0.77 | TDP1 (0.71) | — | |
| SCHEMBL29981733 | 0.77 | TDP1 (0.71) | — | |
| SCHEMBL16617809 | 0.76 | — | — | |
| SCHEMBL459485 | 0.74 | — | — | |
| SCHEMBL1302305 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16950 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137650-A1 | MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) | 11949098 CANADA INC (CA) | 2026-05-21 | — | — | US | claimed |
| EP-4709383-A1 | INVERSE AGONISTS OF RAR RELATED ORPHAN RECEPTORS (RORS) | 11949098 Canada Inc. (CA) | 2026-03-18 | — | — | EP | claimed |
| US-12577324-B2 | Antibodies having specificity to HER4 and uses thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-17 | — | — | US | claimed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| US-20250304910-A1 | METHODS AND COMPOSITIONS FOR INFUSION OF TRANSIENTLY ENGRAFTING, SELECTED POPULATIONS OF ALLOGENEIC LYMPHOCYTES TO TREAT CANCER | THE JOHNS HOPKINS UNIVERSITY | 2025-10-02 | — | — | US | claimed |
| US-20250277045-A1 | DEVELOPMENT AND APPLICATION OF T-CELL ENGAGER THERAPEUTIC AGENT | KEYMED BIOSCIENCES CO.,LTD (CN) | 2025-09-04 | — | — | US | claimed |
| US-12390461-B2 | Modulators of RAR-related orphan receptors (RORs) | 11949098 CANADA INC. (CA) | 2025-08-19 | — | — | US | claimed |
| EP-4593848-A1 | METHODS AND COMPOSITIONS FOR LOCALIZED PRODUCTION AND DELIVERY OF BIOLOGICAL MOLECULES | IYUDA THERAPEUTICS, INC. (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250213688-A1 | METHODS AND COMPOSITIONS FOR LOCALIZED PRODUCTION AND DELIVERY OF BIOLOGICAL MOLECULES | IYUDA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | claimed |
| WO-2025129332-A1 | METHOD OF PROGNOSIS AND MONITORING OF CANCER PATIENT AND OF DETERMINING IMMUNOLOGICAL STATUS OF A SUBJECT | 11949098 CANADA INC. (NUREDCO) C/O JEAN I. TCHERVENKOV (CA) | 2025-06-26 | — | — | WO | claimed |
| EP-1218400-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF IMMUNE DISORDERS | Millennium Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | claimed |
| CN-1354740-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-06-19 | — | — | CN | claimed |
| WO-2002040049-A2 | BLOCKADE OF T CELL MIGRATION INTO EPITHELIAL GVHD TARGET TISSUES | THE GENERAL HOSPITAL CORPORATION (US) | 2002-05-23 | — | — | WO | claimed |
| US-20020058800-A1 | Compositions and methods for the diagnosis and treatment of immune disorders | MILLENNIUM PHARMACEUTICALS, INC. | 2002-05-16 | — | — | US | claimed |
| WO-2001097844-A1 | BISPECIFIC FUSION PROTEIN AND METHOD OF USE FOR ENHANCING EFFECTOR CELL KILLING OF TARGET CELLS | IDEC PHARMACEUTICALS CORPORATION (US) | 2001-12-27 | — | — | WO | claimed |
| US-20010048921-A1 | TREATMENT OF HEMATOLOGIC DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2001-12-06 | — | — | US | claimed |
| WO-2001021641-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-03-29 | — | — | WO | claimed |
| EP-1030675-A2 | TREATMENT OF HEMATOLOGIC DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2000-08-30 | — | — | EP | claimed |
| WO-1999025367-A2 | TREATMENT OF HEMATOLOGIC DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1997035569-A1 | USE OF HEME OXYGENASE INHIBITORS TO TREAT CANCER | WILLIAM HARVEY RESEARCH LIMITED (GB) | 1997-10-02 | — | — | WO | claimed |